Aclaris Therapeutics, Inc.
General ticker "ACRS" information:
- Sector: Health Care
- Industry: Medical - Diagnostics & Research
- Capitalization: $445.4M (TTM average)
Aclaris Therapeutics, Inc. follows the US Stock Market performance with the rate: 45.9%.
Estimated limits based on current volatility of 4.0%: low 3.29$, high 3.57$
Factors to consider:
- Total employees count: 73 (+14.1%) as of 2025
- Company does not operate outside North America (retrieved using AI)
- Top business risk factors: Inability to raise capital, Failure to achieve profitability, Clinical trial failure, Regulatory and compliance, Labor/talent shortage/retention
- Earnings for 6 months up through Q2 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.65$, 4.17$]
- 2026-12-31 to 2027-12-31 estimated range: [1.19$, 3.15$]
Financial Metrics affecting the ACRS estimates:
- Positive: with PPE of -5.6 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: negative Net income
- Positive: 58.56 < Shareholder equity ratio, % of 64.24 <= 69.38
- Positive: Investing cash flow per share per price, % of 13.17 > 2.08
- Positive: -16.84 < Industry operating profit margin (median), % of -16.21
Short-term ACRS quotes
Long-term ACRS plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $31.25MM | $18.72MM | $7.83MM |
| Operating Expenses | $128.61MM | $160.65MM | $84.20MM |
| Operating Income | $-97.36MM | $-141.93MM | $-76.38MM |
| Non-Operating Income | $8.51MM | $9.87MM | $11.45MM |
| R&D Expense | $105.01MM | $120.49MM | $52.65MM |
| Income(Loss) | $-88.85MM | $-132.06MM | $-64.92MM |
| Taxes | $-0.37MM | $0.00MM | $0.00MM |
| Net Income(Loss)* | $-88.48MM | $-132.06MM | $-64.92MM |
| Stockholders Equity | $157.18MM | $155.55MM | $103.08MM |
| Assets | $197.41MM | $220.33MM | $160.46MM |
| Operating Cash Flow | $-78.33MM | $-20.07MM | $-47.11MM |
| Capital expenditure | $1.31MM | $0.12MM | $0.11MM |
| Investing Cash Flow | $46.22MM | $-69.77MM | $48.37MM |
| Financing Cash Flow | $26.71MM | $74.54MM | $-5.86MM |
| Earnings Per Share** | $-1.27 | $-1.71 | $-0.53 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.